Molnupiravir: Mechanism of action, clinical, and translational science by Brian M. Maas, Julie Strizki, Randy R. Miller, Sushma Kumar, Michelle Brown, Matthew G. Johnson, Mickie Cheng, Carisa De Anda, Matthew L. Rizk, Julie A. Stone

Connect to this object online.

Assessment of pharmacokinetics, safety, and tolerability following twice‐daily administration of molnupiravir for 10 days in healthy participants by Marian Iwamoto, Kelly E. Duncan, Prachi K. Wickremasingha, Tian Zhao, Maria V. Liberti, Lieselotte Lemoine, Tatjana Decaesteker, Sylvie Rottey, Brian M. Maas, Gillian Gillespie, S. Aubrey Stoch

Connect to this object online.

A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK‐1654 in healthy Japanese adults by Yuji Orito, Naoyuki Otani, Yuki Matsumoto, Katsukuni Fujimoto, Nobuyuki Oshima, Brian M. Maas, Luzelena Caro, Antonios O. Aliprantis, Kara S. Cox, Osamu Tokumaru, Masaaki Kodama, Hideo Kudo, Hiromitsu Imai, Naoto Uemura

Connect to this object online.

A phase I, randomized, placebo‐controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID‐19 by Keisuke Nakamura, Katsukuni Fujimoto, Chihiro Hasegawa, Ikuo Aoki, Hiroyuki Yoshitsugu, Hiroyuki Ugai, Naoyoshi Yatsuzuka, Yoshiyuki Tanaka, Kenichi Furihata, Brian M. Maas, Prachi K. Wickremasingha, Kelly E. Duncan, Marian Iwamoto, Selwyn A. Stoch, Naoto Uemura

Connect to this object online.

Population pharmacokinetics of molnupiravir in adults with COVID‐19: Lack of clinically important exposure variation across individuals by Sébastien Bihorel, Youfang Cao, Akshita Chawla, Ruthie Birger, Brian M. Maas, Wei Gao, Stefan Roepcke, Susanne Sardella, Rebecca Humphrey, Sindhuri Kondragunta, Bhuvana Jayaraman, Monika Martinho, Wendy Painter, George Painter, Wayne Holman, Carisa De Anda, Michelle L. Brown, Matthew G. Johnson, Amanda Paschke, Matthew L. Rizk, Julie A. Stone

Connect to this object online.